New targeted drug shows promise for hard-to-treat lung cancer
NCT ID NCT06015503
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called PLB1004 in people with advanced or spreading non-small cell lung cancer that has a specific genetic change (EGFR exon 20 insertion). The goal is to see if the drug can shrink tumors and how safe it is. About 139 adults who have already tried other treatments will take the drug and be monitored.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED AND METASTATIC NON-SMALL CELL LUNG CANCER WITH EGFR EXON 20 INSERTION MUTATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Guangdong General Hospital
Guangzhou, Guangdong, 510080, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immune drug outsmart Hard-to-Treat tumors?
- Can a pill plus immunotherapy and targeted radiation shrink lung tumors before surgery?
- Can a targeted drug combo boost chemoradiation in EGFR-Positive lung cancer?
- Cancer drug pralsetinib may change how the body processes other medications
- Blood test may let cancer patients take safe breaks from immunotherapy
- New pill takes on tough lung cancer mutation